We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

QuidelOrtho

Develops, manufactures and markets rapid diagnostic tests that focus on infectious diseases, reproductive health, and... read more Featured Products: More products

Download Mobile App




Ammonia Predicts Prognosis in Hepatitis B Virus‐Related Liver Failure

By LabMedica International staff writers
Posted on 24 Sep 2020
Acute‐on‐chronic liver failure (ACLF) is the rapid deterioration of liver function in chronic liver disease often associated with the development of serious complications such as hepatorenal syndrome and hepatic encephalopathy within a short period of time. More...


Hepatic encephalopathy (HE) is a common feature of acute liver failure and has been reported to be associated with poor outcomes. Ammonia is thought to be central to the pathogenesis of HE, but its role in hepatitis B virus‐related acute‐on‐chronic liver failure (HBV‐ACLF) is unclear.

Clinical Laboratorians at the Zhejiang University (Hangzhou, China) recruited all 127 patients with HBV‐ACLF, defined as total bilirubin (TBIL) ≥ 205 μmol/L and international normalized ratio (INR) ≥ 1.5 according to COSSH‐ACLF criteria, who were treated at their institution between July 2018 and February 2020 for a retrospective study.

Laboratory parameters included total protein, albumin, alanine aminotransferase, aspartate aminotransferase, creatinine, TBIL, arterial ammonia, INR, white blood cell count, platelet count, and blood urea nitrogen. Arterial ammonia was estimated within 24 hours of admission using a Vitros 350 dry chemistry system (Ortho Clinical Diagnostic, Rochester, NY, USA) in heparinized plasma.

The scientists reported that the median ammonia level at enrollment was 55.0 (interquartile range, 36.0‐76.0) and 77 patients (60.6%) had high ammonia at the time of admission. Ammonia level was found to be positively correlated to model for end-stage liver disease (MELD) score and COSSH‐ACLF score. In the study population, there were 61 patients with cirrhosis and 66 patients without cirrhosis. No significant difference between the two groups except that the age of the cirrhosis group was higher than that of the non‐cirrhosis group.

Among the 127 participants, 87 survived and 40 died, representing a 28‐day mortality rate of 31.5%. The mean MELD score, TBIL, INR, white blood cell count, ammonia, and COSSH‐ACLF score were higher among non‐surviving participants; however, the mean age, gender ratio, total protein, albumin, alanine aminotransferase, aspartate aminotransferase, creatinine, blood urea nitrogen, and platelet count were not significantly different between survivors and non‐survivors. Dividing patients according to the ammonia cut‐off value of 73 μmol/L revealed higher ammonia level to be associated with higher alanine aminotransferase, INR, mortality rate, COSSH‐ACLF score and MELD score.

The authors concluded that their results suggest that high ammonia level at admission is an independent factor for predicting short‐term mortality in patients with HBV‐ACLF. Therefore, ammonia levels may represent a therapeutic target for this condition. The study was published on September 11, 2020 in the Journal of Clinical Laboratory Analysis.



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Automated Clinical Chemistry Analyzer
Envoy 500+
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The proposed workflow adds liquid biopsy to detect genetic and molecular signs of cancer in CSF samples already collected during autoimmune encephalitis evaluation. (Image Credit: Shutterstock)

CSF Liquid Biopsy Could Help Distinguish Cancer from Autoimmune Brain Inflammation

Autoimmune encephalitis can cause memory and behavioral changes, seizures, and altered consciousness, but diagnosis can be challenging because cancers involving the brain and central nervous system may... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Ebola remains a rapidly evolving public health threat with high mortality, underscoring the need for timely diagnosis and decentralized testing closer to patients (Image Credit: Adobe Stock)

Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) and ReadyGo Diagnostics Ltd. (Bath, UK) have initiated a collaboration to evaluate ReadyGo’s GoCollect with the Co-Dx PCR platform for blood-based molecular... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.